If you or a loved one has been taking Ozempic and are experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. The medical community has long studied how medications affect digestive function, and recent reports have raised questions about GLP-1 receptor agonists and delayed gastric emptying. This page reviews the latest research and prescribing information to help you understand the potential risks.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. The clinical presentation of gastroparesis overlaps with common side effects reported in Ozempic clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus included nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms are consistent with the clinical presentation of gastroparesis.
Mechanistic pathways linking Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 receptor agonists like semaglutide delay gastric emptying, which can lead to retained gastric contents. This effect is supported by postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Rybelsus or Ozempic tablets, including whether modifying preoperative fasting recommendations or temporarily discontinuing these medications could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for significant gastric retention, which is a hallmark of gastroparesis. Regarding the adequacy of warnings, the Ozempic prescribing information includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions, including serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly list gastroparesis as a specific adverse reaction or warning. The gastrointestinal adverse reactions are described in general terms, and the potential for severe or persistent gastroparesis is not directly addressed. This may raise questions about whether patients and healthcare providers are adequately informed about the risk of developing gastroparesis as a distinct condition rather than transient gastrointestinal side effects.
For affected patients in Massachusetts, attorney-related considerations include the statute of limitations for filing a product liability claim. In Massachusetts, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date the injury was discovered or reasonably should have been discovered. The timeline between exposure to Ozempic and documented harm is critical. Patients who developed symptoms of gastroparesis during or after treatment with Ozempic should document the onset of symptoms, the date of diagnosis, and any medical records linking the condition to the medication. The gastrointestinal adverse reactions in clinical trials occurred more frequently during dose escalation, but symptoms can persist or develop later. Postmarketing reports of pulmonary aspiration indicate that gastric retention can occur even after prolonged use. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific case, including the timing of exposure and harm, to ensure compliance with the statute of limitations.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Massachusetts, the statute of limitations for personal injury claims, including product liability claims related to defective drugs, is generally three years from the date the injury was discovered or reasonably should have been discovered. This means that individuals who believe they developed gastroparesis due to Ozempic should act promptly to preserve their legal rights.
To establish a link, you should document the onset of gastrointestinal symptoms, the date of diagnosis of gastroparesis, and any medical records that show the timing of your Ozempic use. Clinical trial data indicate that gastrointestinal adverse reactions are common with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), and postmarketing reports of pulmonary aspiration highlight the potential for significant gastric retention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Consulting with a medical expert and an attorney can help build your case.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Ozempic exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.